Arcutis Biotherapeutics, Inc. ARQT Debt Maturity - 2027
Debt Maturity - 2027 at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s debt maturity - 2027.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s debt maturity - 2027?
- Arcutis Biotherapeutics, Inc. (ARQT) reported debt maturity - 2027 of $107M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s debt maturity - 2027 changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s debt maturity - 2027 decreased by 0.0% year-over-year, from $107M to $107M.
- What does debt maturity - 2027 mean?
- The specific principal amount of debt obligations scheduled to mature in the year 2027. This metric is essential for assessing the company's liquidity risk and refinancing requirements in a specific future period. It helps investors understand the timing of potential cash outflows related to debt repayment.